Synonym
TRA 418; TRA418; TRA-418;
IUPAC/Chemical Name
(2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentaol 2-((4-(2-((1,1-diphenylethyl)thio)ethyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)oxy)acetate
InChi Key
PGSFVHDYNOMCIC-WZTVWXICSA-N
InChi Code
InChI=1S/C26H27NO4S.C7H17NO5/c1-26(20-9-4-2-5-10-20,21-11-6-3-7-12-21)32-18-16-27-15-17-30-25-22(27)13-8-14-23(25)31-19-24(28)29;1-8-2-4(10)6(12)7(13)5(11)3-9/h2-14H,15-19H2,1H3,(H,28,29);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1
SMILES Code
O=C(O)COC1=C(OCCN2CCSC(C3=CC=CC=C3)(C4=CC=CC=C4)C)C2=CC=C1.O[C@H]([C@H]([C@@H]([C@@H](CO)O)O)O)CNC
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
644.78
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Miyamoto M, Ohno M, Yamada N, Ohtake A, Matsushita T. TRA-418, a thromboxane A2 receptor antagonist and prostacyclin receptor agonist, inhibits platelet- leukocyte interaction in human whole blood. Thromb Haemost. 2010 Oct;104(4):788-95. doi: 10.1160/TH09-09-0622. Epub 2010 Jul 20. PMID: 20664901.
2: Ishizuka T, Higashino H. TP receptor as a therapeutic target in atherosclerosis and related cardiovascular diseases. Recent Pat Cardiovasc Drug Discov. 2006 Nov;1(3):241-7. doi: 10.2174/157489006778777025. PMID: 18221089.
3: Utskarpen A, Slagsvold HH, Iversen TG, Wälchli S, Sandvig K. Transport of ricin from endosomes to the Golgi apparatus is regulated by Rab6A and Rab6A'. Traffic. 2006 Jun;7(6):663-72. doi: 10.1111/j.1600-0854.2006.00418.x. PMID: 16683916.
4: Umemura K, Tsukada H, Kakiuchi T, Yamada N, Matsuura H. PET study of the neuroprotective effect of TRA-418, an antiplatelet agent, in a monkey model of stroke. J Nucl Med. 2005 Nov;46(11):1931-6. PMID: 16269609.
5: Miyamoto M, Yamada N, Ikezawa S, Ohno M, Otake A, Umemura K, Matsushita T. Effects of TRA-418, a novel TP-receptor antagonist, and IP-receptor agonist, on human platelet activation and aggregation. Br J Pharmacol. 2003 Nov;140(5):889-94. doi: 10.1038/sj.bjp.0705499. Epub 2003 Sep 22. PMID: 14504133; PMCID: PMC1574093.
6: Yamada N, Miyamoto M, Isogaya M, Suzuki M, Ikezawa S, Ohno M, Otake A, Umemura K. TRA-418, a novel compound having both thromboxane A(2) receptor antagonistic and prostaglandin I(2) receptor agonistic activities: its antiplatelet effects in human and animal platelets. J Thromb Haemost. 2003 Aug;1(8):1813-9. doi: 10.1046/j.1538-7836.2003.00257.x. PMID: 12911598.
